Chemed Corporation

Chemed Corporation (CHE) Market Cap

Chemed Corporation has a market capitalization of $7.07B.

Price: $532.25

-2.54 (-0.47%)

Market Cap: 7.07B

NYSE · time unavailable

CEO: Kevin J. McNamara

Sector: Healthcare

Industry: Medical - Care Facilities

IPO Date: 1973-05-03

Website: https://www.chemed.com

Chemed Corporation (CHE) - Company Information

Market Cap: 7.07B|Sector: Healthcare

Company Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, doctors, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates through two segments: VITAS and Roto-Rooter segments. The company offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company also provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. Chemed Corporation was incorporated in 1970 and is headquartered in Cincinnati, Ohio.

Analyst Sentiment

58%
Buy

From 4 Active Polls

1Y Forecast: $554.00

▲ +4.1% Potential Upside

Consensus Target Metrics

Low Bound

$475

Median

$554

High Bound

$633

Average

$554

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$554.00
▲ +4.09% Upside
Low Target
$475.00
-11% Risk
Median Target
$554.00
4% Mid
High Target
$633.00
19% Max
Consensus
Hold
3 / 9 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Period EndingTrailing 12MJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024
Market Cap ($M)7,0656,2525,1665,9876,5087,1128,9977,8699,030
Enterprise Value ($M)7,3206,5065,3866,0686,5207,0088,9687,8328,939
Price to Earnings Ratio (P/E)26.7222.7019.4719.5225.1033.8131.3321.7829.81
Price/Earnings-to-Growth Ratio (PEG)9.486.858.4525.4528.853.9117.24
Price to Sales Ratio (P/S)2.729.297.869.3710.4111.4913.9112.3014.90
Price to Book Ratio (P/B)8.607.536.096.116.045.937.617.037.31
Price to Free Cash Flow Ratio (P/FCF)21.8390.2272.6551.0998.5657.92462.2551.72117.31
Enterprise Value to Sales (EV/Sales)9.668.199.4910.4311.3213.8612.2414.75
Enterprise Value to EBITDA (EV/EBITDA)16.9564.1550.7049.6264.0679.8080.0657.3976.30
Debt to Equity Ratio0.590.350.280.160.130.120.120.130.12

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 CHEMED CORP (CHE) — Investment Overview

🧩 Business Model Overview

CHEMED is a two-segment operator with a shared emphasis on service delivery: (1) hospice and home-care services under VITAS, and (2) plumbing, drain, and related repair services under Roto-Rooter.

VITAS (Hospice/Home Care): CARE is delivered through clinician-staffed teams that manage patient episodes under payer rules (primarily government programs and managed care). The operational backbone is patient acquisition via referral and admissions, rapid care mobilization, and high-quality documentation/coding that supports reimbursement continuity.

Roto-Rooter (Plumbing Services): customers generate demand through emergency or scheduled repair needs. The company monetizes by dispatching technicians, installing/repairing plumbing systems, and providing repeat service where plumbing issues recur (drainage, water heaters, sewer lines). Profitability is driven by technician productivity, parts/service mix, and route density.

💰 Revenue Streams & Monetisation Model

VITAS: Hospice revenue is largely episode-based/per-diem driven with additional consideration for ancillary services and payer contract terms. Monetisation is less dependent on transaction-by-transaction selling and more dependent on sustained admission volume, payer mix, and care intensity consistent with reimbursement rules.

Roto-Rooter: Revenue is transactional, tied to service calls and job completion. Monetisation is influenced by average ticket size (repairs versus installs), repeat visit probability for recurring plumbing problems, and labor/parts economics.

Primary margin drivers: (1) labor productivity and staffing stability (clinical staffing for VITAS; technician utilization for Roto-Rooter), (2) payer reimbursement discipline and coding accuracy (VITAS), (3) service density and operational throughput (Roto-Rooter), and (4) working-capital discipline and cost controls across both segments.

🧠 Competitive Advantages & Market Positioning

CHEMED’s moats are best viewed as operating and switching-cost moats created by care continuity (healthcare) and service network density (home services), rather than a purely brand-driven advantage.

  • VITAS / Healthcare: Integrated episode management creates “care continuity” switching costs. Once a patient is in a hospice care pathway, continuity of clinicians, protocols, and documentation reduces friction for referrals and payer administration. The practical barrier is operational execution—staffing readiness, compliance, and care quality—rather than patient “switching” in the short term.
  • VITAS / Geographic density and referral relationships reduce unit costs. Dense coverage areas lower travel time and enable faster response times, which supports both clinical outcomes and cost per visit. The economics strengthen as an operator scales in a region.
  • Roto-Rooter / Dispatch and technician-route density reduce cost-to-serve. Service-network planning (dispatch, scheduling, and technician availability) improves labor utilization and reduces idle time. Faster mobilization and consistent service execution increase throughput and job completion rates.

Competitive benchmarking (explicit peer comparison):

  • Hospice/home-care peers: Amedisys, LHC Group, and Enhabit. These operators compete on regional coverage, admission growth, staffing model, and payer contract terms. CHEMED’s positioning emphasizes operational execution and dense coverage through VITAS, aiming to sustain care continuity economics.
  • Plumbing/drain-service peers: Mr. Rooter, Benjamin Franklin Plumbing, and a large set of local independent plumbing contractors. Competition centers on technician availability, responsiveness, and pricing/quality of repair work. CHEMED’s Roto-Rooter model differentiates through service-network utilization and standardized dispatch/operations.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, CHEMED’s growth outlook is supported by several structural demand forces:

  • Aging demographics and higher incidence of chronic/advanced illness drive a larger population eligible for hospice and home-care services.
  • Site-of-care substitution: continued shift toward care delivered at home rather than in institutional settings supports demand for hospice and home-care providers with strong operational capability.
  • Care model capacity discipline: providers that can staff and comply efficiently capture patient volume without sacrificing documentation quality—an advantage during periods of labor market tightness.
  • Housing stock and infrastructure repair cycle underpin recurring plumbing service needs, including drain and sewer-related maintenance as systems age.
  • Utilization of service networks: as demand fluctuates, operators with dense coverage and efficient dispatch can protect labor productivity and preserve unit economics.

⚠ Risk Factors to Monitor

  • Regulatory and reimbursement pressure (VITAS): Medicare/managed-care rule changes, coding/documentation requirements, and reimbursement dynamics can affect margins and admission throughput.
  • Staffing constraints and wage inflation (both segments): clinical labor shortages can impair response times and care delivery; technician labor costs can compress service margins.
  • Service execution and quality/regulatory compliance (VITAS): documentation accuracy, billing compliance, and clinical quality oversight are core to reimbursement stability.
  • Demand cyclicality (Roto-Rooter): plumbing service volumes are less discretionary than remodeling but can still be influenced by consumer and commercial spending patterns.
  • Competitive intensity: regional entrants and contract competition can pressure pricing or increase customer acquisition costs.
  • Concentration and operational leverage: both segments rely on workforce productivity; operational missteps can have outsized impact on cash generation.

📊 Valuation & Market View

CHEMED typically trades in a framework investors use for service-heavy, cash-generative operating companies:

  • EV/EBITDA and earnings quality: the market places weight on sustainable cash flow, normalized margins, and resilience of operating costs.
  • Segment mix considerations: hospice/home-care economics often receive valuation support when investors view reimbursement stability and care continuity as durable. Home services are evaluated on labor productivity, unit economics, and demand durability.
  • Multiple expansion drivers: margin durability, stable admissions/volume, disciplined operating costs, and credible staffing economics can expand valuation. Multiple compression can follow reimbursement uncertainty, adverse mix, or sustained labor cost pressure.

🔍 Investment Takeaway

CHEMED’s long-term thesis rests on operational moats—not just demand tailwinds. In healthcare, VITAS benefits from care continuity and regional density that support unit-cost advantages and patient pathway stability. In home services, Roto-Rooter’s advantages derive from dispatch-driven network density and labor productivity. The combined model targets resilient cash generation through episode-based care economics and throughput-focused service operations, with key risks centered on reimbursement policy and workforce availability.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for CHE.

marketbeat.com2026-07-29

Chemed Q2 Earnings Call Highlights

Chemed NYSE: CHE reported second-quarter 2026 results marked by stronger-than-expected performance at its VITAS hospice business, while Roto-Rooter delivered revenue growth but continued to face higher customer-acquisition costs.

seekingalpha.com2026-07-29

Chemed Corporation (CHE) Q2 2026 Earnings Call Transcript

Chemed Corporation (CHE) Q2 2026 Earnings Call Transcript

zacks.com2026-07-28

Chemed (CHE) Tops Q2 Earnings and Revenue Estimates

Chemed (CHE) came out with quarterly earnings of $6.06 per share, beating the Zacks Consensus Estimate of $5.55 per share. This compares to earnings of $4.27 per share a year ago.

globenewswire.com2026-07-28

Chemed Reports Second-Quarter 2026 Results

CINCINNATI, July 28, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), the nation's largest providers of end-of-life care, and Roto-Rooter, the nation's largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its second quarter ended June 30, 2026, versus the comparable prior-year period. Results for Quarter Ended June 30, 2026 Consolidated operating results: Revenue increased 8.8% to $673.3 million GAAP Diluted Earnings-per-Share (EPS) of $5.13, an increase of 43.7% Adjusted Diluted EPS of $6.06, an increase of 41.9% VITAS segment operating results: Net Patient Revenue of $443.3 million, an increase of 11.9% Average Daily Census (ADC) of 23,687, an increase of 6.1% Admissions of 19,125, an increase of 9.0% Net Income, excluding certain discrete items, of $61.3 million, an increase of 60.5% Adjusted EBITDA, excluding Medicare Cap, of $80.6 million, an increase of 20.6% Adjusted EBITDA margin, excluding Medicare Cap, of 18.2%, an increase of 196-basis points Roto-Rooter segment operating results: Revenue of $229.9 million, an increase of 3.3% Net Income, excluding certain discrete items, of $33.8 million, essentially flat Adjusted EBITDA of $48.5 million, essentially flat Adjusted EBITDA margin of 21.1%, a decline of 77-basis points VITAS VITAS net revenue was $443.3 million in the second quarter of 2026, which is an increase of 11.9% when compared to the prior-year period.

defenseworld.net2026-07-28

Arrowstreet Capital Limited Partnership Has $57.59 Million Holdings in Chemed Corporation $CHE

Arrowstreet Capital Limited Partnership cut its position in shares of Chemed Corporation (NYSE: CHE) by 1.3% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 152,469 shares of the company's stock after selling 2,050 shares during the period. Arrowstreet Capital

defenseworld.net2026-07-27

Entropy Technologies LP Acquires 5,979 Shares of Chemed Corporation $CHE

Entropy Technologies LP grew its holdings in shares of Chemed Corporation (NYSE: CHE) by 491.7% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,195 shares of the company's stock after buying an additional 5,979 shares during the quarter. Entropy

defenseworld.net2026-07-27

Chemed Corporation $CHE Shares Sold by Gabelli Funds LLC

Gabelli Funds LLC lessened its stake in Chemed Corporation (NYSE: CHE) by 8.3% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 31,138 shares of the company's stock after selling 2,813 shares during the quarter. Gabelli Funds LLC owned

forbes.com2026-07-05

Dividend Growth Stock List: 8 Names Yielding Up To 8.3%

Wall Street analysts have one job: predict where companies' earnings are going in the coming quarter. Sounds simple enough, except said suits aren't so good at it!

globenewswire.com2026-07-01

Chemed To Report Second Quarter 2026 Earnings July 28, Related Conference Call To Be Held On July 29

CINCINNATI, July 01, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the second quarter ended June 30, 2026, on Tuesday, July 28, 2026, following the close of trading on the New York Stock Exchange. Chemed will host a conference call and webcast at 10 a.m.

zacks.com2026-06-26

Should You Hold Chemed Stock in Your Portfolio Now?

CHE's VITAS growth and Roto-Rooter improvements support its outlook, but inflation, tariffs and competitive pressures remain key risks.

zacks.com2026-06-10

AVAH or CHE: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Aveanna Healthcare (AVAH) and Chemed (CHE). But which of these two stocks presents investors with the better value opportunity right now?

globenewswire.com2026-06-08

Roto-Rooter Buys Franchise Territory in Corpus Christi, Rio Grande Valley, and Beaumont, Texas

CINCINNATI, June 08, 2026 (GLOBE NEWSWIRE) -- Roto-Rooter Services Company, a wholly owned subsidiary of Chemed Corporation ("Chemed") (NYSE: CHE) announced it has acquired a formerly independent Roto-Rooter franchise serving 21 counties in south Texas for approximately $12.0 million. The service area includes the cities of Corpus Christi, McAllen, Laredo and Brownsville, Texas.

zacks.com2026-05-25

AVAH vs. CHE: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical - Outpatient and Home Healthcare sector might want to consider either Aveanna Healthcare (AVAH) or Chemed (CHE). But which of these two stocks is more attractive to value investors?

seekingalpha.com2026-05-20

Chemed Corporation (CHE) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Chemed Corporation (CHE) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

globenewswire.com2026-05-18

Chemed Corporation Holds Annual Meeting of Stockholders; Board Declares Quarterly Dividend

CINCINNATI, May 18, 2026 (GLOBE NEWSWIRE) -- Stockholders of Chemed Corporation (NYSE: CHE) today elected a slate of nine directors at the Company's 2026 annual stockholders' meeting. Stockholders ratified the continuation of PricewaterhouseCoopers LLP as the Company's independent accountants for 2026.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-06-30

"CHE reported Q2’26 revenue of $673.3M and net income of $67.7M, translating to EPS of $5.13. QoQ revenue rose to 2.43% (from $657.5M in Q1’26) and net income increased 2.13% (from $66.3M). YoY, revenue grew 8.85% versus Q2’25 ($618.8M) while net income rose 28.96% versus $52.5M, indicating stronger bottom-line momentum than sales. Profitability was mixed across the quarter-to-quarter comparison over the last four quarters: gross profit swung to a negative $198.9M in Q2’26 (gross margin -29.5%) versus positive margins in Q1’26 and prior (e.g., Q1’26 gross margin 30.2%). Despite this gross margin shock, operating income remained positive at $89.2M (operating margin 13.25%), and net margin improved modestly to 10.06% from 10.08% QoQ. Operating cash flow was $84.8M and free cash flow was $69.3M, but shareholder cash returns were dominated by buybacks: $97.5M repurchased shares in Q2’26 (dividends paid were $7.9M). Total shareholder returns appear weak given the stated 1-year price change of -33.84%. Balance sheet resilience remains moderate: total assets were $1.58B with equity of $0.83B, while net debt increased to $254.6M due largely to a lower cash position (cash $40.2M)."

Revenue Growth

Neutral

Revenue +2.43% QoQ (Q2’26 vs Q1’26) and +8.85% YoY (Q2’26 vs Q2’25), showing a steady top-line uptrend.

Profitability

Neutral

Net margin ~flat to slightly lower QoQ (10.06% vs 10.08%), but gross margin collapsed to -29.5% in Q2’26 from +30.2% in Q1’26—suggesting a material cost/COGS anomaly or unusual item impacting gross results. Operating margin stayed healthy at 13.25%.

Cash Flow Quality

Neutral

Operating cash flow of $84.8M supported free cash flow of $69.3M. Shareholder distributions were modest (dividends $7.9M) while buybacks were substantial ($97.5M), supported by operating cash generation this quarter.

Leverage & Balance Sheet

Caution

Total assets rose to $1.58B with equity stable around $0.83B. However, liquidity weakened (cash fell to $40.2M from $16.9M in Q1 but well below prior peaks), and net debt increased to $254.6M.

Shareholder Returns

Neutral

1-year price change is -33.84% and dividend yield is ~0.13%, so total shareholder return is likely negative despite active buybacks.

Analyst Sentiment & Valuation

Neutral

With current price $384.61 and consensus target $554 (substantial upside implied), valuation appears supported by street expectations; however, recent market momentum is clearly negative (1Y down).

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

So What? Chemed’s Q2 2026 performance shows VITAS re-stabilizing after the 2025 Medicare cap disruption while Roto-Rooter manages a tougher marketing landscape. VITAS drove the upside: revenue +11.9% and adjusted EBITDA margin excluding cap of 18.2%, supported by ADC growth (19,125 admissions, +9% YoY) and a meaningful reduction in cap billing limitation (none in Florida; $0.5M in CA, below expectations). Management raised full-year VITAS guidance materially: ADC growth to 5.75%–6.25%, revenue ex-cap to 8.25%–9.25%, and EBITDA margin to 19.0%–19.5%, while cutting expected cap limitation to $7M. Roto-Rooter’s EBITDA was flat but margin declined 77 bps to 21.1% due to paid-lead mix deterioration and higher internet marketing spend; gross margin held. Despite this, management reaffirmed FY EBITDA margin 21.5%–22.5%, relying on ancillary services, collections improvement, and cautious franchise acquisition activity.

AI IconGrowth Catalysts

  • VITAS ADC growth via accelerated admissions from non-preadmission locations while maintaining hospital-based admissions
  • Normalized Medicare cap dynamics: adding Florida Medicare cap cushion and returning to normalized rate of growth after the 2025 cap issue
  • Roto-Rooter commercial momentum driven by commercial business manager program (30 productive managers; ~13% branch revenue lift)
  • Roto-Rooter centralization of water restoration billing/collections improving write-offs and collections efficiency

Business Development

  • Roto-Rooter purchased south Texas franchise territory and assets in June 2026 (including Corpus Christi) for ~$12 million; new population base for contractor portfolio
  • VITAS Medicare cap management in Florida combined program: added $8.9 million to cap cushion in Q2 2026

AI IconFinancial Highlights

  • CHE consolidated revenue +8.8% YoY; adjusted diluted EPS +41.9% YoY in Q2 2026
  • VITAS net revenue $443.3M (+11.9% YoY) driven by +6.1% days of care and +~2.4% geographically weighted average Medicare reimbursement rate increase
  • VITAS Medicare cap/contra-revenue: positive impact of ~455 bps to revenue growth; recorded $0 Medicare cap billing limitation for Florida combined in Q2 2026 and none for expected 2026 fiscal period; CA Medicare cap billing limitation accrued at $0.5M (below $ original expectations)
  • VITAS adjusted EBITDA (excluding Medicare cap) $80.6M (+20.6% YoY); adjusted EBITDA margin excluding Medicare cap 18.2% (no margin change bps explicitly stated)
  • VITAS Q2 2026 admissions 19,125 (+9% YoY); Florida combined hospital admissions mix 42.9% (target stability range 42%–45%); other preadmission locations admissions +8.1% YoY
  • Roto-Rooter total commercial revenue +6.8% YoY; commercial business manager presence yields ~13% branch commercial revenue growth vs -1% in branches without managers
  • Roto-Rooter write-offs improved by $1.3M vs Q2 2025 after centralization (and reduced ~20 employees vs Q2 2025)
  • Roto-Rooter lead mix shift: paid leads rose to ~59% from 54% in Q2 2025; paid leads increase drove +~$3.1M marketing spend YoY
  • Roto-Rooter adjusted EBITDA $48.5M essentially flat YoY; adjusted EBITDA margin 21.1% (down 77 bps YoY) attributed mainly to increased internet marketing costs
  • Roto-Rooter adjusted EBITDA guidance for FY 2026 unchanged: adjusted EBITDA margin 21.5%–22.5%
  • Full-year CHE guidance (excluding specified non-cash/discrete items): adjusted diluted EPS $25.00–$25.75; midpoint $+7.8% vs 2025 adjusted diluted EPS $20.21; assumes 24.5% effective corporate tax rate and 13.5M diluted shares

AI IconCapital Funding

  • Consolidated operating cash flow exceeded $173 million in Q2 2026
  • Company highlighted minimal leverage enabling aggressive share repurchases; no explicit repurchase dollar amount disclosed in transcript

AI IconStrategy & Ops

  • VITAS: ADC growth achieved while keeping full-time equivalents (FTEs) below budgeted targets; staffing monitored for quality/hiring/retention and does not impede growth expectations
  • VITAS: average length-of-stay 101.2 days (vs 137.1 days prior year), median length-of-stay 16 days (down 4 days YoY)
  • Roto-Rooter: centralized water restoration billing/collections continued; expected disruption to job processing improving sequentially (water restoration avg revenue per job -3.5% in Q2 vs ~-13% in Q1)
  • Roto-Rooter: actively working with independent contractor segment to mitigate challenges and regain growth trajectory (independent contractor revenue -1.9% YoY in Q2)

AI IconMarket Outlook

  • VITAS FY 2026 raised guidance: ADC growth 5.75%–6.25% (prior 4.5%–5.5%)
  • VITAS FY 2026 raised guidance: revenue growth excluding Medicare cap 8.25%–9.25% (prior 6.5%–7.5%)
  • VITAS FY 2026 revised EBITDA margin excluding Medicare cap 19.0%–19.5% (prior 18.0%–18.5%)
  • VITAS FY 2026 Medicare cap billing limitation reduced to $7 million (prior $9.5 million)
  • Roto-Rooter FY 2026 guidance unchanged: revenue growth 3%–3.5%; adjusted EBITDA margin 21.5%–22.5%
  • Management reiterated guidance is updated normally once per year at the midyear/second-quarter cadence unless unusual developments occur

AI IconRisks & Headwinds

  • Roto-Rooter internet marketing pressure: reliance on paid Google leads increased (free-to-paid shift); adjusted EBITDA margin down 77 bps YoY despite stable gross margin
  • Roto-Rooter lead ‘leakage on marketing expenses’ persists; limited visibility on how internet marketing providers (Google) evolve
  • Roto-Rooter centralization still in transition: water restoration job economics improving sequentially but near-term disruption expected to continue improving through the year
  • VITAS Medicare cap risk sensitivity: Florida cap cushion depends on maintaining de novo and admission mix discipline; new starts timing/pace could affect cap exposure (risk discussed by analyst; management response partially truncated)
  • VITAS state CON constraints: moratorium on new centers may influence ability to apply for new CONs; moratorium due to end in November but could be extended
  • Transcript truncation prevents full detail on the Medicare cap deployment/risk framework

Q&A: Analyst Interest

  • Topic: VITAS long-term ADC/revenue sustainability and Florida mix durability: Management emphasized KPI-based resource deployment and asserted the 42%–45% hospital mix is sustainable. They tied long-term confidence to returning to normalized growth rates post-2025 cap issue, and visibility into 2027 demand/strategy execution.
  • Topic: Roto-Rooter EBITDA margin miss drivers (SG&A/lead mix) and expected stabilization: Management stated the Q2 EBITDA shortfall vs estimate was roughly ~$1M, driven by marketing costs. They argued it was not enough to change the long-term outlook; offsets include ancillary add-ons, improving collections, and continuing to stabilize lead economics despite Google/free-lead pressure.
  • Topic: Roto-Rooter service-line expansion vs investment discipline and implications for growth: Management described why past service-line expansions had mixed results (notably water restoration success but other trials struggling). They cited low acquisition cost for add-ons to existing customer base, discussed stopping a loss-making water-quality initiative, and said no new service-line was currently at a level requiring public discussion.

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the CHE Q2 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for CHE.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (CHE)

© 2026 Stock Market Info — Chemed Corporation (CHE) Financial Profile